Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Key Inclusion Criteria:

• Age ≥18 years

• Diagnosed with NSCLC, Colorectal adenocarcinoma, Pancreatic adenocarcinoma,Endometrial Cancer or any other solid tumor

• Tumors must harbor a KRAS G12D variant mutation and subject must be HLA-C08:02positive, HLA-A11:01 or HLA-A*11:02 positive in at least one allele

• Subject has advanced solid cancer, defined as unresectable, advanced, and/ormetastatic disease (Stage III or IV) after at least 1 line of approved systemicstandard of care (SOC) treatment regimen and for which there are no availablecurative treatment options.

• Presence of at least 1 measurable lesion per RECIST v1.1

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at the timeof enrollment

Key Exclusion Criteria:

• Any other primary malignancy within the 3 years prior to enrollment (except fornon-melanoma skin cancer, carcinoma in situ (eg, cervix, bladder, breast) orlow-grade prostate cancer

• Known, active primary central nervous system (CNS) malignancy

• History of prior adoptive cell and gene therapy, allogeneic stem cell transplant orsolid organ transplantation.

• History of stroke or transient ischemic attack within the 12 months prior toenrollment.

• History of clinically significant cardiac disease within the 6 months prior toenrollment or heart failure at any time prior to enrollment.

• Systemic therapy within at least 2 weeks or 3 half-lives, whichever is shorter,prior to enrollment.

• Any form of primary immunodeficiency.

• Active immune-mediated disease requiring systemic steroids or otherimmunosuppressive treatment (except if related to prior checkpoint inhibitortherapy)

• Female of childbearing potential who is lactating or breast feeding at the time ofenrollment

• Prior treatment with pan-KRAS or KRAS G12D targeting agents unless presence of KRASG12D mutation is confirmed after the completion of treatment with pan-KRAS or KRASG12D targeting agents.